Company

Bristol Myers Squibb

2 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 18, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Baraclude (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling changes to entecavir; does not report clinical trial outcomes or comparative efficacy data.

Regulatory UpdateEntecavir Bristol Myers Squibb

Reported

Approval date2026-08-18

Product formulations approvedEntecavir 0.5 mg tablet; Entecavir 1 mg tab…

JUL 22, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Revlimid (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval of labeling changes for lenalidomide; describes a regulatory action, not clinical trial evidence or efficacy data.

Regulatory UpdateBristol Myers Squibb Lenalidomide